| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | NEUTRAL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.22▼ | 2.21▲ | 2.20▲ | 2.26▼ | 2.60▼ |
| MA10 | 2.22 | 2.20▲ | 2.21▲ | 2.64▼ | 2.53▼ |
| MA20 | 2.22▲ | 2.21▲ | 2.22▲ | 2.74▼ | 2.12▲ |
| MA50 | 2.20▲ | 2.23▼ | 2.41▼ | 2.53▼ | 2.78▼ |
| MA100 | 2.21▲ | 2.47▼ | 2.78▼ | 2.07▲ | 4.32▼ |
| MA200 | 2.21▲ | 2.77▼ | 2.69▼ | 2.39▼ | 6.90▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▲ | 0.006▲ | 0.019▲ | -0.117▼ | 0.102▲ |
| RSI | 55.506▲ | 50.044▲ | 42.688▼ | 38.484▼ | 47.046▼ |
| STOCH | 67.500 | 58.269 | 24.405 | 4.045▼ | 53.124 |
| WILL %R | -33.333 | -26.667 | -60.714 | -94.040▼ | -63.252 |
| CCI | 12.963 | 85.800 | 30.172 | -94.132 | -44.398 |
|
Wednesday, October 01, 2025 04:09 AM
The Phase 1b trial will evaluate the safety and tolerability of cemsidomide, an IKZF1/3 degrader, and dexamethasone in combination with elranatamab as a second line or later therapy for patients with ...
|
|
Friday, September 26, 2025 06:51 AM
Barclays has identified several standout opportunities in the Oncology and Inflammation & Immunology (I&I) space, spotlighting companies advancing innovative protein degradation platforms and targeted ...
|
|
Monday, September 22, 2025 06:01 AM
Analysts have set 12-month price targets for C4 Therapeutics, revealing an average target of $7.0, a high estimate of $8.00, and a low estimate of $6.00. This upward trend is evident, with the current ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 30/09/25 | 2.20 | 2.2493 | 2.16 | 2.22 | 890,172 |
| 29/09/25 | 2.24 | 2.305 | 2.18 | 2.23 | 1,165,711 |
| 26/09/25 | 2.22 | 2.265 | 2.13 | 2.23 | 1,753,200 |
| 25/09/25 | 2.42 | 2.42 | 2.17 | 2.19 | 2,898,800 |
| 24/09/25 | 2.58 | 2.625 | 2.415 | 2.42 | 1,774,400 |
| 23/09/25 | 2.80 | 2.83 | 2.56 | 2.59 | 3,260,700 |
| 22/09/25 | 3.30 | 3.43 | 2.575 | 2.61 | 3,996,900 |
| 19/09/25 | 3.37 | 3.375 | 3.13 | 3.16 | 883,200 |
| 18/09/25 | 3.41 | 3.58 | 3.265 | 3.32 | 1,266,500 |
| 17/09/25 | 3.41 | 3.47 | 3.21 | 3.38 | 1,336,300 |
|
|
||||
|
|
||||
|
|